|  |  |  |  |  | POAF | LOS(days) | ||
---|---|---|---|---|---|---|---|---|---|
Reference | Surgery type | Study design | Control group | Double- blinding | Jadad Score | NAC | Control | NAC | Control |
Ozaydin et al. [12] | CABG and/or valve | RCT (prospective) | Placebo | Yes | 4 | 3/58 | 12/57 | 7.7 ± 3 | 7.9 ± 4.2 |
Eren et al. [13] | CABG | RCT (prospective) | Placebo | Yes | 3 | 2/10 | 1/10 | NA | NA |
Orhan et al. [14] | CABG | RCT | Routine protocol | No | 3 | 0/10 | 1/10 | 7.2 ± 0.42 | 7.3 ± 0.48 |
El-Hamamsy et al. [15] | CABG | RCT (prospective) | Placebo | Yes | 3 | 4/50 | 6/50 | 5.4 ± 2.3 | 5.3 ± 2.5 |
Haase et al. [16]# | CABG and/or valve | RCT | Placebo | Yes | 5 | 19/30 | 16/30 | 8(7-11) | 8(7-11) |
Wijeysundera et al. [17] | CABG and/or valve | RCT | Placebo | Yes | 5 | 50/88 | 58/87 | NA | NA |
Peker et al. [18] | CABG | RCT (prospective) | Placebo | Yes | 4 | 0/19 | 2/21 | NA | NA |
Kim et al. [19] | CABG | RCT | Placebo | Yes | 4 | 4/24 | 8/24 | 11.3 ± 6.3 | 10.5 ± 4.5 |